<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462148</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00032807</org_study_id>
    <nct_id>NCT02462148</nct_id>
  </id_info>
  <brief_title>Perineural Steroids for Peripheral Nerve Blocks</brief_title>
  <official_title>Perineural Steroids for Saphenous Peripheral Nerve Blocks: An Equivalency Dosing Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at the efficacy of dexamethasone for prolongation of peripheral nerve
      blocks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized, double-blinded, placebo-controlled trial is to examine if
      dexamethasone given perineurally as an adjuvant to the nerve block will prolong the time to
      recovery from sensory nerve block from a saphenous (or adductor canal) nerve block. The
      primary outcome will be time to resolution of the nerve block as assessed by pinprick over
      the saphenous nerve distribution. If this primary end point is met, this study will also
      serve as an equivalency dosing study comparing 1 mg of perineural dexamethasone to 4 mg of
      perineural dexamethasone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Sensory Nerve Block</measure>
    <time_frame>12 to 48 hours</time_frame>
    <description>The primary outcome will be time to resolution of the nerve block as assessed by pinprick over the saphenous nerve distribution. Testing will occur every two hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verbal Pain Scores</measure>
    <time_frame>0 to 30 hours</time_frame>
    <description>Verbal Pain Scores will be compared between groups as obtained every six hours during hospitalization. Patients will be asked to provide verbal pain scores both at rest and with movement on a scale of 0-10 (0 being no pain and 10 being the worst pain). These scores will be taken at 0, 6, 12, 18, 24, and 30 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Post Operative Nausea and Vomiting</measure>
    <time_frame>0 to 30 hours</time_frame>
    <description>Number of participants that experienced nausea and vomiting was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic Complications</measure>
    <time_frame>throughout study completion, up to 48 hours</time_frame>
    <description>Each patient will be followed for neurologic complications (paresthesias, etc) if they should occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Opioid Use and Consumption</measure>
    <time_frame>0-30 hours</time_frame>
    <description>Amount of opioid use and consumption was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Opioid Analgesic Request</measure>
    <time_frame>0 to 36 hours</time_frame>
    <description>Time it took for the first opioid analgesic request was recorded.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Used in nerve block mixture</description>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <other_name>Dexamethasone Sodium Phosphate Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Used in nerve block mixture</description>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Bupivacaine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>Used in nerve block mixture</description>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Adrenaline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Saphenous Peripheral Nerve Block</intervention_name>
    <description>Peripheral nerve block.</description>
    <arm_group_label>1 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>4 mg Perineural Dexamethasone Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Adductor Canal Peripheral Nerve Block</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective robotic medial MAKO partial knee arthroplasty

          -  agreed to a regional anesthesia technique

        Exclusion Criteria:

          -  contraindications to regional anesthesia

          -  presence of a progressive neurological deficit

          -  a pre-existing coagulopathy, infection

          -  insulin and non-insulin dependent diabetes mellitus

          -  systemic use of corticosteroids within 30 days of surgery

          -  chronic use of an opioid analgesic (&gt;3 months or a combined total of more than 40 mg
             Oxycodone equivalents a day)

          -  pregnancy

          -  a prior history of an adverse event (for example: psychosis) or an allergy to
             dexamethasone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryl S Henshaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 1, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <results_first_submitted>June 1, 2018</results_first_submitted>
  <results_first_submitted_qc>July 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2018</results_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthesia</keyword>
  <keyword>Anesthesia, Conduction</keyword>
  <keyword>Anesthesia, Local</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Saphenous</keyword>
  <keyword>Adductor Canal</keyword>
  <keyword>Nerve Block</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Preanesthetic Medication</keyword>
  <keyword>Perioperative Period</keyword>
  <keyword>Peripheral Nerve Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 7, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02462148/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>4 mg Perineural Dexamethasone Group</title>
          <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
        </group>
        <group group_id="P2">
          <title>1 mg Perineural Dexamethasone Group</title>
          <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Group</title>
          <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>4 mg Perineural Dexamethasone Group</title>
          <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
        </group>
        <group group_id="B2">
          <title>1 mg Perineural Dexamethasone Group</title>
          <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
        </group>
        <group group_id="B3">
          <title>Placebo Group</title>
          <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="8.7"/>
                    <measurement group_id="B2" value="63.3" spread="8.9"/>
                    <measurement group_id="B3" value="59.2" spread="9.1"/>
                    <measurement group_id="B4" value="62.7" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Sensory Nerve Block</title>
        <description>The primary outcome will be time to resolution of the nerve block as assessed by pinprick over the saphenous nerve distribution. Testing will occur every two hours.</description>
        <time_frame>12 to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4 mg Perineural Dexamethasone Group</title>
            <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O2">
            <title>1 mg Perineural Dexamethasone Group</title>
            <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Sensory Nerve Block</title>
          <description>The primary outcome will be time to resolution of the nerve block as assessed by pinprick over the saphenous nerve distribution. Testing will occur every two hours.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.00" spread="11.18"/>
                    <measurement group_id="O2" value="31.75" spread="10.50"/>
                    <measurement group_id="O3" value="29.67" spread="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Verbal Pain Scores</title>
        <description>Verbal Pain Scores will be compared between groups as obtained every six hours during hospitalization. Patients will be asked to provide verbal pain scores both at rest and with movement on a scale of 0-10 (0 being no pain and 10 being the worst pain). These scores will be taken at 0, 6, 12, 18, 24, and 30 hours.</description>
        <time_frame>0 to 30 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4mg Perineural Dexamethasone</title>
            <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Resting pain score 0 hours post-op</description>
          </group>
          <group group_id="O2">
            <title>1 mg Perineural Dexamethasone</title>
            <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Resting pain score 0 hours post-op</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
Resting Pain score 0 hours post-op</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Pain Scores</title>
          <description>Verbal Pain Scores will be compared between groups as obtained every six hours during hospitalization. Patients will be asked to provide verbal pain scores both at rest and with movement on a scale of 0-10 (0 being no pain and 10 being the worst pain). These scores will be taken at 0, 6, 12, 18, 24, and 30 hours.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.5"/>
                    <measurement group_id="O2" value="2.3" spread="2.5"/>
                    <measurement group_id="O3" value="2.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.7"/>
                    <measurement group_id="O2" value="1.3" spread="2.3"/>
                    <measurement group_id="O3" value="1.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.8"/>
                    <measurement group_id="O2" value="2.1" spread="2.5"/>
                    <measurement group_id="O3" value="3.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.9"/>
                    <measurement group_id="O2" value="1.8" spread="2.1"/>
                    <measurement group_id="O3" value="3.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.7"/>
                    <measurement group_id="O2" value="1.8" spread="2.0"/>
                    <measurement group_id="O3" value="3.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.2"/>
                    <measurement group_id="O2" value="3.1" spread="2.7"/>
                    <measurement group_id="O3" value="4.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Post Operative Nausea and Vomiting</title>
        <description>Number of participants that experienced nausea and vomiting was recorded.</description>
        <time_frame>0 to 30 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4 mg Perineural Dexamethasone Group</title>
            <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O2">
            <title>1 mg Perineural Dexamethasone Group</title>
            <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Post Operative Nausea and Vomiting</title>
          <description>Number of participants that experienced nausea and vomiting was recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurologic Complications</title>
        <description>Each patient will be followed for neurologic complications (paresthesias, etc) if they should occur.</description>
        <time_frame>throughout study completion, up to 48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4 mg Perineural Dexamethasone Group</title>
            <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O2">
            <title>1 mg Perineural Dexamethasone Group</title>
            <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Neurologic Complications</title>
          <description>Each patient will be followed for neurologic complications (paresthesias, etc) if they should occur.</description>
          <units>neurological complications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Opioid Use and Consumption</title>
        <description>Amount of opioid use and consumption was recorded.</description>
        <time_frame>0-30 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4 mg Perineural Dexamethasone Group</title>
            <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O2">
            <title>1 mg Perineural Dexamethasone Group</title>
            <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Post Operative Opioid Use and Consumption</title>
          <description>Amount of opioid use and consumption was recorded.</description>
          <units>mg oxycodone equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.16" spread="24.35"/>
                    <measurement group_id="O2" value="26.04" spread="24.81"/>
                    <measurement group_id="O3" value="42.33" spread="26.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Opioid Analgesic Request</title>
        <description>Time it took for the first opioid analgesic request was recorded.</description>
        <time_frame>0 to 36 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>4 mg Perineural Dexamethasone Group</title>
            <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O2">
            <title>1 mg Perineural Dexamethasone Group</title>
            <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Group</title>
            <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Opioid Analgesic Request</title>
          <description>Time it took for the first opioid analgesic request was recorded.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="686.18" spread="420.41"/>
                    <measurement group_id="O2" value="654.97" spread="384.05"/>
                    <measurement group_id="O3" value="658.17" spread="424.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 72 hours post-operatively.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>4 mg Perineural Dexamethasone Group</title>
          <description>4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
        </group>
        <group group_id="E2">
          <title>1 mg Perineural Dexamethasone Group</title>
          <description>1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
Dexamethasone: Used in nerve block mixture
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Group</title>
          <description>This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
Bupivacaine: Used in nerve block mixture
Epinephrine: Used in nerve block mixture
Saphenous Peripheral Nerve Block: Peripheral nerve block.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jimmy Turner</name_or_title>
      <organization>Wake Forest Baptist Health</organization>
      <phone>3368064498</phone>
      <email>jturner@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

